Reuters: Sanofi, Genzyme agree on deal structure

The hot Sanofi-Aventis ($SNY) news this morning was that Genzyme ($GENZ) agreed to open its books to the French drugmaker. The two companies had inked a confidentiality agreement, Bloomberg reported, a big step forward in their progress toward a potential merger.

Although Sanofi's tender offer at $69 per share has been open for months, the companies have only recently been negotiating a higher price. "The discussions are continuing," Sanofi said in a regulatory filing. An analyst predicted a deal within the next few months at $74 per share, plus $5 to $10 in additional payments according to the performance of Genzyme's potential multiple sclerosis treatment Lemtrada.

But by press time, the deal reportedly had moved to a faster track. Word was that Genzyme and Sanofi actually agreed to a deal structure. Sources told Reuters that the agreement will indeed include the contingent value rights tied to Lemtrada performance. One predicted a deal within the next two weeks.

- check out the story from Reuters
- see the Bloomberg news

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.